慢性阻塞性肺疾病和哮喘的早期诊断与治疗——一项随机对照试验
研究通过病例发现法在社区识别未诊断的慢阻肺或哮喘成人,将595例中508例随机分为肺科医生指导组253例和常规照护组255例。干预组呼吸疾病相关就医年化率低于常规照护组(0.53 vs 1.12次/人年;发生率比0.48;95%CI 0.36~0.63;P<0.001)。12个月时圣乔治呼吸问卷评分和CAT评分两组均下降,干预组下降更多,FEV1干预组增加119ml,常规照护组增加22ml。
要点
- 社区病例发现可识别未诊断的慢阻肺或哮喘成人。
- 肺科医生指导的早期治疗降低呼吸疾病相关就医年化率。
- 干预组12个月时生活质量、症状负担和FEV1改善优于常规照护组。
核心结论
- 在采用社区识别未诊断哮喘或慢阻肺策略的试验中,接受肺科医生指导治疗者后续呼吸疾病相关就医少于常规照护者。
研究设计与样本
- 多中心、随机、对照试验,采用病例发现法在社区识别有呼吸道症状且未诊断肺病的成人。
- 共访谈38353人,595例发现未诊断慢阻肺或哮喘,508例随机分组:干预组253例,常规照护组255例。
- 干预组由肺科医生和哮喘-慢阻肺教育者评估并启动指南为基础的治疗,常规照护组由初级保健医生常规照护。
主要发现
- 主要结局事件年化率干预组0.53次/人年 vs 常规照护组1.12次/人年(发生率比0.48;95%CI 0.36~0.63;P<0.001)。
- 12个月时SGRQ评分较基线下降干预组10.2分 vs 常规照护组6.8分(差值-3.5分;95%CI -6.0~-0.9)。
- 12个月时CAT评分较基线下降干预组3.8分 vs 常规照护组2.6分(差值-1.3分;95%CI -2.4~-0.1)。
- 12个月时FEV1增加干预组119ml vs 常规照护组22ml(差值94ml;95%CI 50~138)。
- 不良事件发生率两组相似。
临床怎么用
- 作者结论支持在社区识别未诊断哮喘或慢阻肺成人后,由肺科医生指导启动指南为基础的治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many persons with chronic obstructive pulmonary disease (COPD) or asthma have not received a diagnosis, so their respiratory symptoms remain largely untreated. METHODS: We used a case-finding method to identify adults in the community with respiratory symptoms without diagnosed lung disease. Participants who were found to have undiagnosed COPD or asthma on spirometry were enrolled in a multicenter, randomized, controlled trial to determine whether early diagnosis and treatment reduces health care utilization for respiratory illness and improves health outcomes. Participants were assigned to receive the intervention (evaluation by a pulmonologist and an asthma-COPD educator who were instructed to initiate guideline-based care) or usual care by their primary care practitioner. The primary outcome was the annualized rate of participant-initiated health care utilization for respiratory illness. Secondary outcomes included changes from baseline to 1 year in disease-specific quality of life, as assessed with the St. George Respiratory Questionnaire (SGRQ; scores range from 0 to 100, with lower scores indicating better health status); symptom burden, as assessed with the COPD Assessment Test (CAT; scores range from 0 to 40, with lower scores indicating better health status); and forced expiratory volume in 1 second (FEV1). RESULTS: Of 38,353 persons interviewed, 595 were found to have undiagnosed COPD or asthma and 508 underwent randomization: 253 were assigned to the intervention group and 255 to the usual-care group. The annualized rate of a primary-outcome event was lower in the intervention group than in the usual-care group (0.53 vs. 1.12 events per person-year; incidence rate ratio, 0.48; 95% confidence interval [CI], 0.36 to 0.63; P<0.001). At 12 months, the SGRQ score was lower than the baseline score by 10.2 points in the intervention group and by 6.8 points in the usual-care group (difference, -3.5 points; 95% CI, -6.0 to -0.9), and the CAT score was lower than the baseline score by 3.8 points and 2.6 points, respectively (difference, -1.3 points; 95% CI, -2.4 to -0.1). The FEV1 increased by 119 ml in the intervention group and by 22 ml in the usual-care group (difference, 94 ml; 95% CI, 50 to 138). The incidence of adverse events was similar in the trial groups. CONCLUSIONS: In this trial in which a strategy was used to identify adults in the community with undiagnosed asthma or COPD, those who received pulmonologist-directed treatment had less subsequent health care utilization for respiratory illness than those who received usual care. (Funded by Canadian Institutes of Health Research; UCAP ClinicalTrials.gov number, NCT03148210.).
引用
- Aaron SD, Vandemheen KL, Whitmore GA, et al. Early Diagnosis and Treatment of COPD and Asthma - A Randomized, Controlled Trial. N Engl J Med. 2024. PMID: 38767248. doi:10.1056/NEJMoa2401389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。